-
2021-09-24
1-800 Contacts Acquires Ditto
It will combine Premium Vision, 6over6 and Ditto
into a separate business unit focused on providing
B2B solutions.more >
-
2021-07-23
IMI 2021 YEARLY DIGEST
The International Myopia Institute (IMI) Yearly Digest
highlights new research considered to be of importance
since the publication of the first series of IMI white papers.more >
-
2021-07-22
Making Cataract Surgery Child’s Play
The FDA’s first approved drop for the prevention of
intraoperative miosis and reduction of postoperative pain
in pediatric patients undergoing cataract surgery has arrived. But does it warrant the excitement?more >
-
2021-06-28
Study sheds new light on the function of a sight-saving growth factor
Researchers at the National Eye Institute (NEI) have
determined how certain short protein fragments,
called peptides, can protect neuronal cells found in the light-sensing retina layer at the back of the eye.more >
-
2021-03-25
New Era Arrives in Glaucoma Medication, With Transformative Tech
Market Scope estimates pharmaceutical companies
will earn $1.9 billion from glaucoma medications
in the US in 2021, after discounts and rebates, and $4.8 billion worldwide.more >
-
2021-03-22
Steady Growth, New Technologies Will Drive Retinal Surgery Device Market to $1.36 Billion in 2026
The retinal surgical device market is expected
to total more than $1.14 billion in 2021,
with revenue rising to nearly $1.36 billion in 2026, according to a Market Scope report.more >
-
CureSight and EyeSwiftPro of NovaSight have been granted with the CE mark approval.
It's announce that CureSight, the
treatment system for amblyopia, and
EyeSwiftPro, the visual assesment system, have been granted with the CE mark approval.2022-01-25
-
Multifocal lens co Addon Optics raises $12M
The Israeli company's platform integrates
an off the shelf single focal lens with a proprietary
flexible lens to create a high-quality progressive lens.2022-01-05
-
BELKIN Vision Selected to Receive €17.5M from EU Innovation Council
BELKIN Vision, announced that it has been selected
to receive €17.5M of blended financing in grants and equity
from the European Innovation Council Accelerator (EIC)2021-12-21
-
Direct selective laser trabeculoplasty in open angle glaucoma study design: a multicentre, randomised, controlled, investigator-masked trial (GLAUrious)
This trial aims to test the hypothesis that
translimbal DSLT is effective and not inferior to
selective laser trabeculoplasty (SLT) in reducing intraocular pressure (IOP) in open angle glaucoma (OAG).2021-09-01
